Rice Hall James & Associates LLC Takes Position in Repligen Co. (NASDAQ:RGEN)

Rice Hall James & Associates LLC purchased a new stake in Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 15,391 shares of the biotechnology company's stock, valued at approximately $2,215,000.

Several other institutional investors have also added to or reduced their stakes in the company. CIBC Asset Management Inc boosted its stake in Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 81 shares during the period. Congress Asset Management Co. boosted its stake in Repligen by 12.4% in the 4th quarter. Congress Asset Management Co. now owns 116,620 shares of the biotechnology company's stock valued at $16,786,000 after purchasing an additional 12,856 shares during the period. Rhumbline Advisers boosted its stake in Repligen by 1.9% in the 4th quarter. Rhumbline Advisers now owns 146,149 shares of the biotechnology company's stock valued at $21,037,000 after purchasing an additional 2,739 shares during the period. Van ECK Associates Corp raised its holdings in Repligen by 7.8% in the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock valued at $6,078,000 after acquiring an additional 3,066 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Repligen by 79.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 457,065 shares of the biotechnology company's stock valued at $65,395,000 after acquiring an additional 203,011 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RGEN. HC Wainwright reaffirmed a "buy" rating and issued a $180.00 price objective on shares of Repligen in a report on Friday. Canaccord Genuity Group lifted their price objective on Repligen from $165.00 to $170.00 and gave the company a "hold" rating in a report on Friday. Royal Bank of Canada lifted their price objective on Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a report on Friday. Wolfe Research began coverage on Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating for the company. Finally, Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $183.36.

Repligen Trading Down 2.3 %

Repligen stock traded down $3.68 during trading hours on Friday, hitting $158.99. The stock had a trading volume of 795,356 shares, compared to its average volume of 609,046. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The stock has a market cap of $8.91 billion, a price-to-earnings ratio of -429.69, a P/E/G ratio of 4.23 and a beta of 0.99. Repligen Co. has a one year low of $113.50 and a one year high of $203.13. The business's 50 day simple moving average is $155.17 and its 200-day simple moving average is $148.81.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The firm had revenue of $167.55 million during the quarter, compared to the consensus estimate of $167.58 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. On average, equities analysts predict that Repligen Co. will post 1.54 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.